Bioglutide™ Phase 2 Deep Dive – ADA 2025 & ENDO 2025 Highlights

Updated: August 17, 2025 • Educational content only, not medical advice.

Biomed Industries’ Bioglutide™ (NA‑931), a novel oral quadruple agonist targeting IGF‑1, GLP‑1, GIP, and glucagon receptors, made waves at two major 2025 conferences: ADA 2025 in June and ENDO 2025 in July.

Key Takeaways from ADA 2025 Presentation

  • Phase 2 trial (13 weeks, randomized, double‑blind, placebo‑controlled, 125 patients): up to 13.8 % weight loss at 150 mg daily; ~12.4 % more than placebo. [source]
  • 72 % of treated patients achieved ≥12 % weight loss vs just 2 % in the placebo group. [source]
  • Safety: Mostly mild TEAEs, including nausea (~7.3 %) and diarrhea (~6.3 %).

Additional Insights from ENDO 2025

  • Reaffirmed mechanism: simultaneous modulation of four hormone pathways. [source]
  • Phase 2 data supports an oral alternative to injectables, with strong safety and efficacy.

Why This Matters

Bioglutide’s oral formulation offers adherence advantages over injectable therapies, and its multi-pathway approach could yield enhanced metabolic benefits with fewer side effects.

FAQs

Is Bioglutide available now?
No—still investigational, pending Phase 3 trials and regulatory approvals.

How does it compare to injectables?
Phase 2 weight loss results appear competitive, but direct head-to-head data is not yet published.

Disclaimer

 This content is intended for informational and educational purposes only and is not intended to promote or sell any product. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves.

Back to blog